A Victim Of Its Own Success? U-Turn On Taro Merger Could Be A Strategic Call By India’s Sun Pharma
This article was originally published in PharmAsia News
Executive Summary
Taro’s strong performance since Sun took a majority stake has complicated the Indian pharma’s merger plans, but analysts say the story may still evolve.
You may also be interested in...
Sun’s Generic Doxil Clears FDA; Janssen Uses Alternative Manufacturing Process
FDA approval of the first generic version of Janssen’s Doxil to curtail drug’s shortage; agency also permits Janssen to use an alternative manufacturing process.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.